Lupin announces closure of US FDA Inspection at its Injectable Facility with Zero 483 Observations

Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed an inspection of its Injectable facility in Nagpur, India. The inspection of the facility was carried out from June 10 to June 13, 2024, and concluded with zero 483 observations.

Nilesh Gupta, Managing Director, Lupin said, "We are pleased to have a successful outcome of the U.S. FDA inspection at our Nagpur injectable facility with zero observations. This reflects our dedication to uphold the highest quality and compliance standards across our facilities."

Shares of Lupin Limited was last trading in BSE at Rs. 1605.35 as compared to the previous close of Rs. 1605.40. The total number of shares traded during the day was 17679 in over 864 trades.

The stock hit an intraday high of Rs. 1621.00 and intraday low of 1601.65. The net turnover during the day was Rs. 28403785.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA Inspection InjectableFacility Zero483Observation Nagpur India